Nasdaq approves Biosergen's delisting from First North, conditional on Flerie merger
Nasdaq has approved Biosergen AB's application to delist from the First North Growth Market. The delisting is conditional upon the completion of its merger with Flerie AB.
Nasdaq has approved Biosergen AB's application for the delisting of its shares from the Nasdaq First North Growth Market. This approval is conditional on the Swedish Companies Registration Office granting permission for the company's merger with Flerie AB (publ) to proceed.
Biosergen applied for the delisting on September 15, 2026. The move is in connection with the planned merger with Flerie, a transaction initially announced on June 26, 2026. Extraordinary general meetings of both Biosergen and Flerie approved the merger on August 6, 2026.
The stock exchange's decision to approve the delisting application was made on September 17, 2026. The final execution of the delisting now awaits the Swedish Companies Registration Office's formal approval to finalize the merger.
Upon successful completion of the merger and subsequent regulatory approval, Biosergen's shares will be removed from the Nasdaq First North Growth Market.